We stand at the threshold of a new era for pharmaceutical supply chains, driven by breakthroughs in personalised medicine, the rising prevalence of biologics, and the integration of digital
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant
